RNA编辑酶ADAR1在前列腺癌肿瘤免疫中的研究进展

doi:10.3760/cma.j.cn441417-20250318-21001

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (21): 3522-3525.DOI: 10.3760/cma.j.cn441417-20250318-21001

• 前列腺专题 • 下一篇

RNA编辑酶ADAR1在前列腺癌肿瘤免疫中的研究进展

李协照蔡志煅袁耀基朱锐周泽文徐桂彬赵海波

广州医科大学附属第五医院泌尿外科，广州 510700

收稿日期:2025-03-18 出版日期:2025-11-01 发布日期:2025-11-18
通讯作者: 赵海波，Email：hibyzhao@126.com
基金资助:
国家自然科学基金（82103359）；广东省医学科研基金（B2023345）；广州医科大学科研能力提升项目（02-410-2302085XM）

Research progress of RNA editing enzyme ADAR1 in tumor immunity of prostate cancer

Li Xiezhao, Cai Zhiduan, Yuan Yaoji, Zhu Rui, Zhou Zewen, Xu Guibin, Zhao Haibo

Department of Urology, Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China

Received:2025-03-18 Online:2025-11-01 Published:2025-11-18
Contact: Zhao Haibo, Email: hibyzhao@126.com
Supported by:
National Natural Science Foundation of China (82103359); Guangdong Provincial Medical Research Fund (B2023345); Guangzhou Medical University Scientific Research Ability Promotion Project (02-410-2302085XM)

摘要/Abstract

摘要： RNA编辑酶腺苷脱氨酶1（adenosine deaminase acting on RNA 1，ADAR1）在肿瘤领域中的研究备受关注，包括前列腺癌。作为第一个被发现的腺苷转变为肌苷（adenosine to inosine，A-to-I）RNA编辑酶，ADAR1在肿瘤免疫逃逸的研究越来越多。因此，本文对ADAR1的作用机制及其在前列腺癌肿瘤免疫作用综述，为挖掘ADAR1在前列腺癌中作为潜在诊治靶点提供有益总结。

关键词: 前列腺癌, RNA编辑酶, ADAR1, 肿瘤免疫逃逸, 进展

Abstract:

Adenosine deaminase acting on RNA 1 (ADAR1) has attracted much attention in the field of cancer, including prostate cancer. As the first identified A-to-I RNA editing enzyme (converting adenosine to inosine), ADAR1 is increasingly being studied in the context of tumor immune evasion. Therefore, this article reviews the mechanisms of action of ADAR1 and its role in tumor immunity in prostate cancer, providing a valuable summary for exploring ADAR1 as a potential therapeutic target in the diagnosis and treatment of prostate cancer.

Key words: Prostate cancer, RNA editing enzyme, ADAR1, Tumor immune escape, Progress

李协照蔡志煅袁耀基朱锐周泽文徐桂彬赵海波. RNA编辑酶ADAR1在前列腺癌肿瘤免疫中的研究进展[J]. 国际医药卫生导报, 2025, 31(21): 3522-3525.

Li Xiezhao, Cai Zhiduan, Yuan Yaoji, Zhu Rui, Zhou Zewen, Xu Guibin, Zhao Haibo. Research progress of RNA editing enzyme ADAR1 in tumor immunity of prostate cancer[J]. International Medicine and Health Guidance News, 2025, 31(21): 3522-3525.

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74(3):229-263. DOI: 10.3322/caac.21834.
[2] Yang JH, Nie Y, Zhao Q, et al. Intracellular localization of differentially regulated RNA-specific adenosine deaminase isoforms in inflammation[J]. J Biol Chem, 2003, 278(46):45833-42. DOI: 10.1074/jbc.M308612200.
[3] Liddicoat BJ, Piskol R, Chalk AM, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself[J]. Science, 2015, 349(6252):1115-20. DOI: 10.1126/science.aac7049.
[4] Yu Z, Chen T, Cao X. RNA editing by ADAR1 marks dsRNA as "self"[J]. Cell Res, 2015,25(12):1283-1284. DOI: 10.1038/cr.2015.135.
[5] Xu LD, Öhman M. ADAR1 Editing and its role in cancer[J]. Genes, 2018, 10(1): 12. DOI: 10.3390/genes10010012.
[6] Zhang J, Dang F, Ren J, et al. Biochemical aspects of PD-L1 regulation in cancer immunotherapy[J]. Trends Biochem Sci, 2018, 43(12):1014-1032. DOI: 10.1016/j.tibs.2018.09.004.
[7] Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade[J]. Nat Rev Immunol, 2020, 20(1):25-39. DOI: 10.1038/s41577-019-0218-4.
[8] Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: a role of PD-L1 Induction in the determination of pro-and antitumor immunity[J]. Clin Cancer Res, 2016, 22(10):2329-2334. DOI: 10.1158/1078-0432.CCR-16-0224.
[9] Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J]. Br J Cancer, 2015, 112(9):1501-1509. DOI: 10.1038/bjc.2015.101.
[10] Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression[J]. Cell Rep, 2017, 19(6):1189-1201. DOI: 10.1016/j.celrep.2017.04.031.
[11] Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer[J]. Cancer Sci, 2018, 109(1):43-53. DOI: 10.1111/cas.13424.
[12] Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy[J]. J Neuroinflammation, 2018, 15(1):290. DOI: 10.1186/s12974-018-1330-2.
[13] Wu B, Peisley A, Richards C, et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5[J]. Cell, 2013, 152(1-2):276-89. DOI: 10.1016/j.cell.2012.11.048.
[14] Broquet AH, Hirata Y, McAllister CS, et al. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium[J]. J Immunol, 2011, 186(3):1618-1626. DOI: 10.4049/jimmunol.1002862.
[15] Zamanian-Daryoush M, Mogensen TH, DiDonato JA, et al. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase[J]. Mol Cell Biol, 2000, 20(4):1278-1290. DOI: 10.1128/MCB.20.4.1278-1290.2000.
[16] Pichlmair A, Schulz O, Tan CP, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection[J]. J Virol, 2009, 83(20):10761-10769. DOI: 10.1128/JVI.00770-09.
[17] Hartner JC, Walkley CR, Lu J, et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling[J]. Nat Immunol, 2009,10(1):109-115. DOI: 10.1038/ni.1680.
[18] Mannion NM, Greenwood SM, Young R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA[J]. Cell Rep, 2014, 9(4):1482-1494. DOI: 10.1016/j.celrep.2014.10.041.
[19] Pestal K, Funk CC, Snyder JM, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development[J]. Immunity, 2015, 43(5):933-944. DOI: 10.1016/j.immuni.2015.11.001.
[20] Ishizuka JJ, Manguso RT, Cheruiyot CK, et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade[J]. Nature, 2019,565(7737):43-48. DOI: 10.1038/s41586-018-0768-9.
[21] Kung CP, Maggi LB, Weber JD. The role of RNA editing in cancer development and metabolic disorders[J]. Front Endocrinol (Lausanne), 2018, 9:762. DOI: 10.3389/fendo.2018.00762.
[22] Jiang Q, Crews LA, Barrett CL, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia[J]. Proc Natl Acad Sci USA, 2013,110(3):1041-1046. DOI: 10.1073/pnas.1213021110.
[23] Xufeng R, Nie D, Yang Q, et al. RNA editing enzyme ADAR1 is required for early T cell development[J]. Blood Sci, 2020, 2(1):27-32. DOI: 10.1097/BS9.0000000000000039.
[24] Young AA, Bohlin HE, Pierce JR, et al. Suppression of double-stranded RNA sensing in cancer: molecular mechanisms and therapeutic potential[J]. Biochem Soc Trans, 2024, 52(5):2035-2045. DOI: 10.1042/BST20230727.
[25] Gannon HS, Zou T, Kiessling MK, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells[J]. Nat Commun, 2018, 9(1):5450. DOI: 10.1038/s41467-018-07824-4.
[26] Chan TH, Qamra A, Tan KT, et al. ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer[J]. Gastroenterology, 2016, 151(4):637-650.e10. DOI: 10.1053/j.gastro.2016.06.043.
[27] Taverna G , Grizzi F , Melegari S , et al. ADAR1 is highly expressed in primary prostate cancer and correlated with CD8+ T-lymphocytes density[J]. European Urology Supplements, 2018, 17(2):e86.DOI:10.1016/S1569-9056(18)30912-6.
[28] Wang X, Li J, Zhu Y, et al. Targeting ADAR1 with a small molecule for the treatment of prostate cancer[J]. Nat Cancer, 2025, 6(3):474-492. DOI: 10.1038/s43018-025-00907-4.

RNA编辑酶ADAR1在前列腺癌肿瘤免疫中的研究进展

Research progress of RNA editing enzyme ADAR1 in tumor immunity of prostate cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵洲刘为朋李宗睿王睿智胡宝光. 高血压大鼠模型的研究现状 [J]. 国际医药卫生导报, 2025, 31(9): 1465-1470.
[2]	昝兴淳. 通督调神针刺治疗脑卒中后吞咽障碍的研究进展与展望 [J]. 国际医药卫生导报, 2025, 31(9): 1470-1474.
[3]	李强. 超声引导下射频消融治疗甲状腺微小乳头状癌的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1258-1260.
[4]	洪金全黄震宇黄惠炆黄豪博. 胸苷酸合成酶基因在肿瘤发生发展中的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1260-1265.
[5]	蒋萌赵静如刘惠刘庆新. 自噬与缺血性脑血管疾病的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1265-1269.
[6]	刘汉清孙银萍赵强任帅. MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1270-1274.
[7]	朱鹏唐文玲覃刚. 结直肠癌中微小RNA功能及临床价值进展 [J]. 国际医药卫生导报, 2025, 31(6): 886-890.
[8]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.
[9]	张子怡孙大康. TRIM22抗HIV-1作用机制研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 918-922.
[10]	易伟米倩倩赵洁李博宇王丹. 彩色多普勒血流成像在球后血流动力学检测中的应用 [J]. 国际医药卫生导报, 2025, 31(6): 922-926.
[11]	陈秀珠张凯韦岩笑丛晨阳. 甲状腺相关眼病的药物治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 927-929.
[12]	陈媛高梦昕王晶陈雨钦蔡超孙红玲. 基于网络的决策辅助工具在前列腺癌患者治疗决策中应用效果的meta分析[J]. 国际医药卫生导报, 2025, 31(5): 706-712.
[13]	李晓童于胜强. 肾小管细胞来源外泌体在肾纤维化中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 712-718.
[14]	张涵孙婷王延飞张肖林车娟. 移植后淋巴组织增生性疾病在儿童扁桃体腺样体肥大中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 752-757.
[15]	莫家婵范万峰姜兴岳. 基于磁共振成像的影像组学在垂体腺瘤中的应用现状及进展 [J]. 国际医药卫生导报, 2025, 31(5): 757-760.